nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—CDKL3—female reproductive system—fallopian tube cancer	0.0218	0.0218	CbGeAlD
Sorafenib—CDKL2—female reproductive system—fallopian tube cancer	0.0199	0.0199	CbGeAlD
Sorafenib—MAPK15—female reproductive system—fallopian tube cancer	0.018	0.018	CbGeAlD
Sorafenib—CDK7—uterine cervix—fallopian tube cancer	0.014	0.014	CbGeAlD
Sorafenib—ZAK—uterine cervix—fallopian tube cancer	0.0121	0.0121	CbGeAlD
Sorafenib—HIPK4—female reproductive system—fallopian tube cancer	0.0121	0.0121	CbGeAlD
Sorafenib—HIPK3—uterine cervix—fallopian tube cancer	0.0118	0.0118	CbGeAlD
Sorafenib—CDK7—uterus—fallopian tube cancer	0.0117	0.0117	CbGeAlD
Sorafenib—TIE1—epithelium—fallopian tube cancer	0.0111	0.0111	CbGeAlD
Sorafenib—TIE1—uterine cervix—fallopian tube cancer	0.0111	0.0111	CbGeAlD
Sorafenib—ZAK—endometrium—fallopian tube cancer	0.0109	0.0109	CbGeAlD
Sorafenib—HIPK3—endometrium—fallopian tube cancer	0.0107	0.0107	CbGeAlD
Sorafenib—MAPK11—female reproductive system—fallopian tube cancer	0.0107	0.0107	CbGeAlD
Sorafenib—CDK7—female reproductive system—fallopian tube cancer	0.0105	0.0105	CbGeAlD
Sorafenib—AURKC—female reproductive system—fallopian tube cancer	0.0103	0.0103	CbGeAlD
Sorafenib—ZAK—uterus—fallopian tube cancer	0.0101	0.0101	CbGeAlD
Sorafenib—MAPK11—female gonad—fallopian tube cancer	0.00969	0.00969	CbGeAlD
Sorafenib—BRAF—endometrium—fallopian tube cancer	0.00959	0.00959	CbGeAlD
Sorafenib—EPHA6—female reproductive system—fallopian tube cancer	0.00955	0.00955	CbGeAlD
Sorafenib—CDK7—female gonad—fallopian tube cancer	0.00953	0.00953	CbGeAlD
Sorafenib—TAOK2—female gonad—fallopian tube cancer	0.00946	0.00946	CbGeAlD
Sorafenib—TAOK2—vagina—fallopian tube cancer	0.0094	0.0094	CbGeAlD
Sorafenib—TIE1—uterus—fallopian tube cancer	0.00921	0.00921	CbGeAlD
Sorafenib—FLT4—epithelium—fallopian tube cancer	0.00921	0.00921	CbGeAlD
Sorafenib—ZAK—female reproductive system—fallopian tube cancer	0.00906	0.00906	CbGeAlD
Sorafenib—FGFR1—uterine cervix—fallopian tube cancer	0.00901	0.00901	CbGeAlD
Sorafenib—HIPK3—female reproductive system—fallopian tube cancer	0.00886	0.00886	CbGeAlD
Sorafenib—BRAF—uterus—fallopian tube cancer	0.00883	0.00883	CbGeAlD
Sorafenib—MAP3K19—female reproductive system—fallopian tube cancer	0.00868	0.00868	CbGeAlD
Sorafenib—MAP3K7—uterine cervix—fallopian tube cancer	0.00853	0.00853	CbGeAlD
Sorafenib—EPHX2—uterus—fallopian tube cancer	0.00844	0.00844	CbGeAlD
Sorafenib—MKNK2—epithelium—fallopian tube cancer	0.00834	0.00834	CbGeAlD
Sorafenib—TIE1—female reproductive system—fallopian tube cancer	0.00828	0.00828	CbGeAlD
Sorafenib—MKNK2—uterine cervix—fallopian tube cancer	0.00827	0.00827	CbGeAlD
Sorafenib—ZAK—female gonad—fallopian tube cancer	0.00824	0.00824	CbGeAlD
Sorafenib—ZAK—vagina—fallopian tube cancer	0.00819	0.00819	CbGeAlD
Sorafenib—MKNK1—uterine cervix—fallopian tube cancer	0.00816	0.00816	CbGeAlD
Sorafenib—RET—epithelium—fallopian tube cancer	0.00813	0.00813	CbGeAlD
Sorafenib—HIPK3—female gonad—fallopian tube cancer	0.00806	0.00806	CbGeAlD
Sorafenib—HIPK3—vagina—fallopian tube cancer	0.00802	0.00802	CbGeAlD
Sorafenib—MAP3K7—endometrium—fallopian tube cancer	0.00772	0.00772	CbGeAlD
Sorafenib—TIE1—female gonad—fallopian tube cancer	0.00754	0.00754	CbGeAlD
Sorafenib—FLT3—female reproductive system—fallopian tube cancer	0.00754	0.00754	CbGeAlD
Sorafenib—FGFR1—uterus—fallopian tube cancer	0.00751	0.00751	CbGeAlD
Sorafenib—MKNK2—endometrium—fallopian tube cancer	0.00748	0.00748	CbGeAlD
Sorafenib—RALBP1—uterine cervix—fallopian tube cancer	0.00747	0.00747	CbGeAlD
Sorafenib—MKNK1—endometrium—fallopian tube cancer	0.00738	0.00738	CbGeAlD
Sorafenib—BRAF—female gonad—fallopian tube cancer	0.00723	0.00723	CbGeAlD
Sorafenib—BRAF—vagina—fallopian tube cancer	0.00718	0.00718	CbGeAlD
Sorafenib—FLT1—epithelium—fallopian tube cancer	0.00716	0.00716	CbGeAlD
Sorafenib—RAF1—epithelium—fallopian tube cancer	0.00712	0.00712	CbGeAlD
Sorafenib—MAP3K7—uterus—fallopian tube cancer	0.00711	0.00711	CbGeAlD
Sorafenib—FLT1—uterine cervix—fallopian tube cancer	0.0071	0.0071	CbGeAlD
Sorafenib—RAF1—uterine cervix—fallopian tube cancer	0.00706	0.00706	CbGeAlD
Sorafenib—EPHB6—uterine cervix—fallopian tube cancer	0.00702	0.00702	CbGeAlD
Sorafenib—EPHX2—female gonad—fallopian tube cancer	0.00691	0.00691	CbGeAlD
Sorafenib—MKNK2—uterus—fallopian tube cancer	0.00689	0.00689	CbGeAlD
Sorafenib—EPHX2—vagina—fallopian tube cancer	0.00686	0.00686	CbGeAlD
Sorafenib—FLT3—female gonad—fallopian tube cancer	0.00686	0.00686	CbGeAlD
Sorafenib—FLT4—female reproductive system—fallopian tube cancer	0.00684	0.00684	CbGeAlD
Sorafenib—RALBP1—endometrium—fallopian tube cancer	0.00675	0.00675	CbGeAlD
Sorafenib—STK10—uterine cervix—fallopian tube cancer	0.00672	0.00672	CbGeAlD
Sorafenib—FLT1—endometrium—fallopian tube cancer	0.00642	0.00642	CbGeAlD
Sorafenib—RAF1—endometrium—fallopian tube cancer	0.00639	0.00639	CbGeAlD
Sorafenib—EPHB6—endometrium—fallopian tube cancer	0.00635	0.00635	CbGeAlD
Sorafenib—FLT4—female gonad—fallopian tube cancer	0.00623	0.00623	CbGeAlD
Sorafenib—RALBP1—uterus—fallopian tube cancer	0.00622	0.00622	CbGeAlD
Sorafenib—MKNK2—female reproductive system—fallopian tube cancer	0.0062	0.0062	CbGeAlD
Sorafenib—FGFR1—female gonad—fallopian tube cancer	0.00614	0.00614	CbGeAlD
Sorafenib—MKNK1—female reproductive system—fallopian tube cancer	0.00612	0.00612	CbGeAlD
Sorafenib—FGFR1—vagina—fallopian tube cancer	0.00611	0.00611	CbGeAlD
Sorafenib—KDR—epithelium—fallopian tube cancer	0.00606	0.00606	CbGeAlD
Sorafenib—KDR—uterine cervix—fallopian tube cancer	0.006	0.006	CbGeAlD
Sorafenib—MAP2K5—uterine cervix—fallopian tube cancer	0.006	0.006	CbGeAlD
Sorafenib—FLT1—uterus—fallopian tube cancer	0.00592	0.00592	CbGeAlD
Sorafenib—RAF1—uterus—fallopian tube cancer	0.00589	0.00589	CbGeAlD
Sorafenib—CSF1R—uterine cervix—fallopian tube cancer	0.00586	0.00586	CbGeAlD
Sorafenib—MAP3K7—female gonad—fallopian tube cancer	0.00582	0.00582	CbGeAlD
Sorafenib—MAP3K7—vagina—fallopian tube cancer	0.00578	0.00578	CbGeAlD
Sorafenib—MKNK2—female gonad—fallopian tube cancer	0.00564	0.00564	CbGeAlD
Sorafenib—STK10—uterus—fallopian tube cancer	0.0056	0.0056	CbGeAlD
Sorafenib—MKNK2—vagina—fallopian tube cancer	0.0056	0.0056	CbGeAlD
Sorafenib—RALBP1—female reproductive system—fallopian tube cancer	0.00559	0.00559	CbGeAlD
Sorafenib—MKNK1—female gonad—fallopian tube cancer	0.00557	0.00557	CbGeAlD
Sorafenib—PDGFRA—uterus—fallopian tube cancer	0.00555	0.00555	CbGeAlD
Sorafenib—MKNK1—vagina—fallopian tube cancer	0.00553	0.00553	CbGeAlD
Sorafenib—KDR—endometrium—fallopian tube cancer	0.00543	0.00543	CbGeAlD
Sorafenib—MAP2K5—endometrium—fallopian tube cancer	0.00543	0.00543	CbGeAlD
Sorafenib—KIT—epithelium—fallopian tube cancer	0.00537	0.00537	CbGeAlD
Sorafenib—FLT1—female reproductive system—fallopian tube cancer	0.00532	0.00532	CbGeAlD
Sorafenib—KIT—uterine cervix—fallopian tube cancer	0.00532	0.00532	CbGeAlD
Sorafenib—CSF1R—endometrium—fallopian tube cancer	0.0053	0.0053	CbGeAlD
Sorafenib—RAF1—female reproductive system—fallopian tube cancer	0.00529	0.00529	CbGeAlD
Sorafenib—PDGFRB—epithelium—fallopian tube cancer	0.00524	0.00524	CbGeAlD
Sorafenib—PDGFRB—uterine cervix—fallopian tube cancer	0.0052	0.0052	CbGeAlD
Sorafenib—RALBP1—female gonad—fallopian tube cancer	0.00509	0.00509	CbGeAlD
Sorafenib—RALBP1—vagina—fallopian tube cancer	0.00506	0.00506	CbGeAlD
Sorafenib—STK10—female reproductive system—fallopian tube cancer	0.00504	0.00504	CbGeAlD
Sorafenib—KDR—uterus—fallopian tube cancer	0.005	0.005	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—fallopian tube cancer	0.00499	0.00499	CbGeAlD
Sorafenib—CSF1R—uterus—fallopian tube cancer	0.00488	0.00488	CbGeAlD
Sorafenib—FLT1—female gonad—fallopian tube cancer	0.00484	0.00484	CbGeAlD
Sorafenib—RAF1—female gonad—fallopian tube cancer	0.00481	0.00481	CbGeAlD
Sorafenib—FLT1—vagina—fallopian tube cancer	0.00481	0.00481	CbGeAlD
Sorafenib—KIT—endometrium—fallopian tube cancer	0.00481	0.00481	CbGeAlD
Sorafenib—EPHB6—female gonad—fallopian tube cancer	0.00479	0.00479	CbGeAlD
Sorafenib—RAF1—vagina—fallopian tube cancer	0.00478	0.00478	CbGeAlD
Sorafenib—EPHB6—vagina—fallopian tube cancer	0.00476	0.00476	CbGeAlD
Sorafenib—PDGFRB—endometrium—fallopian tube cancer	0.0047	0.0047	CbGeAlD
Sorafenib—STK10—female gonad—fallopian tube cancer	0.00458	0.00458	CbGeAlD
Sorafenib—STK10—vagina—fallopian tube cancer	0.00456	0.00456	CbGeAlD
Sorafenib—PDGFRA—female gonad—fallopian tube cancer	0.00454	0.00454	CbGeAlD
Sorafenib—PDGFRA—vagina—fallopian tube cancer	0.00451	0.00451	CbGeAlD
Sorafenib—KDR—female reproductive system—fallopian tube cancer	0.0045	0.0045	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—fallopian tube cancer	0.0045	0.0045	CbGeAlD
Sorafenib—KIT—uterus—fallopian tube cancer	0.00443	0.00443	CbGeAlD
Sorafenib—CSF1R—female reproductive system—fallopian tube cancer	0.00439	0.00439	CbGeAlD
Sorafenib—PDGFRB—uterus—fallopian tube cancer	0.00433	0.00433	CbGeAlD
Sorafenib—HTR2B—uterine cervix—fallopian tube cancer	0.00412	0.00412	CbGeAlD
Sorafenib—MAP2K5—female gonad—fallopian tube cancer	0.00409	0.00409	CbGeAlD
Sorafenib—KDR—female gonad—fallopian tube cancer	0.00409	0.00409	CbGeAlD
Sorafenib—KDR—vagina—fallopian tube cancer	0.00407	0.00407	CbGeAlD
Sorafenib—MAP2K5—vagina—fallopian tube cancer	0.00407	0.00407	CbGeAlD
Sorafenib—CSF1R—female gonad—fallopian tube cancer	0.00399	0.00399	CbGeAlD
Sorafenib—KIT—female reproductive system—fallopian tube cancer	0.00399	0.00399	CbGeAlD
Sorafenib—CSF1R—vagina—fallopian tube cancer	0.00397	0.00397	CbGeAlD
Sorafenib—PDGFRB—female reproductive system—fallopian tube cancer	0.00389	0.00389	CbGeAlD
Sorafenib—HTR2B—endometrium—fallopian tube cancer	0.00372	0.00372	CbGeAlD
Sorafenib—KIT—female gonad—fallopian tube cancer	0.00363	0.00363	CbGeAlD
Sorafenib—KIT—vagina—fallopian tube cancer	0.00361	0.00361	CbGeAlD
Sorafenib—PDGFRB—female gonad—fallopian tube cancer	0.00354	0.00354	CbGeAlD
Sorafenib—PDGFRB—vagina—fallopian tube cancer	0.00352	0.00352	CbGeAlD
Sorafenib—ABCC4—uterus—fallopian tube cancer	0.00345	0.00345	CbGeAlD
Sorafenib—HTR2B—uterus—fallopian tube cancer	0.00343	0.00343	CbGeAlD
Sorafenib—HTR2C—female reproductive system—fallopian tube cancer	0.00328	0.00328	CbGeAlD
Sorafenib—ABCC4—female reproductive system—fallopian tube cancer	0.0031	0.0031	CbGeAlD
Sorafenib—HTR2B—female reproductive system—fallopian tube cancer	0.00308	0.00308	CbGeAlD
Sorafenib—ABCC2—female reproductive system—fallopian tube cancer	0.003	0.003	CbGeAlD
Sorafenib—ABCG2—uterine cervix—fallopian tube cancer	0.00292	0.00292	CbGeAlD
Sorafenib—ABCC4—female gonad—fallopian tube cancer	0.00282	0.00282	CbGeAlD
Sorafenib—HTR2B—vagina—fallopian tube cancer	0.00279	0.00279	CbGeAlD
Sorafenib—CYP2C8—endometrium—fallopian tube cancer	0.00272	0.00272	CbGeAlD
Sorafenib—CYP3A5—uterine cervix—fallopian tube cancer	0.00271	0.00271	CbGeAlD
Sorafenib—ABCG2—endometrium—fallopian tube cancer	0.00264	0.00264	CbGeAlD
Sorafenib—ABCG2—uterus—fallopian tube cancer	0.00243	0.00243	CbGeAlD
Sorafenib—CYP2C19—vagina—fallopian tube cancer	0.00233	0.00233	CbGeAlD
Sorafenib—CYP2C8—female reproductive system—fallopian tube cancer	0.00225	0.00225	CbGeAlD
Sorafenib—CYP2C8—vagina—fallopian tube cancer	0.00204	0.00204	CbGeAlD
Sorafenib—CYP2B6—female reproductive system—fallopian tube cancer	0.00202	0.00202	CbGeAlD
Sorafenib—CYP2C9—female reproductive system—fallopian tube cancer	0.002	0.002	CbGeAlD
Sorafenib—ABCG2—female gonad—fallopian tube cancer	0.00199	0.00199	CbGeAlD
Sorafenib—ABCG2—vagina—fallopian tube cancer	0.00198	0.00198	CbGeAlD
Sorafenib—CYP3A5—female gonad—fallopian tube cancer	0.00185	0.00185	CbGeAlD
Sorafenib—CYP3A5—vagina—fallopian tube cancer	0.00184	0.00184	CbGeAlD
Sorafenib—CYP2B6—vagina—fallopian tube cancer	0.00183	0.00183	CbGeAlD
Sorafenib—CYP3A4—female reproductive system—fallopian tube cancer	0.00152	0.00152	CbGeAlD
Sorafenib—CYP2D6—female reproductive system—fallopian tube cancer	0.0015	0.0015	CbGeAlD
Sorafenib—ABCB1—epithelium—fallopian tube cancer	0.00145	0.00145	CbGeAlD
Sorafenib—ABCB1—uterine cervix—fallopian tube cancer	0.00144	0.00144	CbGeAlD
Sorafenib—CYP2D6—female gonad—fallopian tube cancer	0.00137	0.00137	CbGeAlD
Sorafenib—ABCB1—endometrium—fallopian tube cancer	0.0013	0.0013	CbGeAlD
Sorafenib—ABCB1—uterus—fallopian tube cancer	0.0012	0.0012	CbGeAlD
Sorafenib—ABCB1—female reproductive system—fallopian tube cancer	0.00108	0.00108	CbGeAlD
Sorafenib—ABCB1—female gonad—fallopian tube cancer	0.000982	0.000982	CbGeAlD
Sorafenib—ABCB1—vagina—fallopian tube cancer	0.000976	0.000976	CbGeAlD
